Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

AZD3293

Before and after

From cloudy to clear: visualising complex data privacy information

Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.

Cuttsy + Cuttsy

- PMLiVE

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

The agreement covers the development of new lead tau morphomer candidates

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

Carer with patient

The invisible influence on trial retention: why caregivers must be part of the plan

Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.

Cuttsy + Cuttsy

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

The Site Factor - printed report

Where it all began: why we wrote ‘The Site Factor’

Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.

Cuttsy + Cuttsy

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The rare neurodegenerative disorder has no cure and no approved treatments

phthalmologist, optometrist checking child, little girl vision looking for problems and caring for eye

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

Cuttsy + Cuttsy

Fan image of Site Report

New Cuttsy+Cuttsy research shows why site support matters more than ever

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links